


Brighter

We are a human innovation company.

Our purpose is to improve the lives of millions of people living with diabetes while driving innovation in the healthcare sector.



Q2
Interim Report
April — June 2022

Contents.

Human innovation.	3
CEO Comment.	4
Why invest in Brighter?	6
Significant events during and after the quarter.	7
Financial summary.	8
Comments on the financial results.	9
Sales.	11
Business risks and other information.	12
Financial statements.	13
Notes.	19
Financial calendar.	24
Submission of interim report.	25
About Brighter.	26



4.

CEO Comment – Actiste commercialization accelerates.

The first half of the year has been a mix of great achievements and challenges.

6.


Why invest in Brighter?

Our products and solutions - in line with the global trends of digital healthcare.

11.

Sales.

Brighter continues to focus on several key markets in the Middle East and Southeast Asia.



Human innovation.

On a mission to improve the lives of millions of people living with diabetes.



A human innovation company.

Brighter addresses common public health challenges by introducing groundbreaking technology and innovative services. We aim to improve health outcomes and wellbeing amongst the global population and facilitate increased efficiency throughout the healthcare system. Currently Brighter has offices in Stockholm, Dubai, Jakarta and New York.

This is Brighter.



Brighter.

Diabetes Management as a Service. Proactive and data-driven healthcare in Diabetes.

Read more [here](#).

Fully owned.



Nectarine Health.

IoT and Deep Learning to assist senior living and independent living facilities.

Read more [here](#).

Fully controlled subsidiary.

Actiste® commercialization accelerates.

The first half of 2022 has been a mix of great achievements and challenges for Brighter. Many positive things have happened, and we have reached significant milestones.

Strong commercial progress in Qatar.

Chief among our achievements is the launch of Actiste® Diabetes Management as a Service (ADMS) in one of our focus markets – Qatar – where the solution is now being used with the aim of improving the lives of people living with diabetes. Following the launch, we are heavily focused on recruiting even more patients and hospitals in the country. This is proceeding according to plan.

Closer to commercialization in the United Arab Emirates.

In the United Arab Emirates (UAE), we have been working hard to obtain Radio and Telecommunications Terminal Equipment type approval, which is a requirement for our Actiste® devices to comply with specific local technical standards. In July, after the end of the period, we received this. All that remains before the company can move forward with commercialization in the country is Internet of Things (IoT) registration approval and exemption for permanent roaming.

Another exciting development is that we have received ethical approval for the Actiste® pilot project that Brighter will perform together with the Emirates Health Services (EHS) in the UAE. A number of healthcare facilities have already signed up to participate in the pilot. We have also been granted import-clearance approval, satisfying the final local requirements that were needed to start the pilot.



100 patients identified for Indonesian Actiste® Mini user study.

In Indonesia, Brighter continues to have intense interaction with clinics, universities and governments in order to speed up commercialisation. In the West Java user study in Indonesia, 100 orally and insulin-treated type 2 diabetes patients have now been identified, comprising 65 patients from a public hospital and 35 patients from a private hospital.

Progress in Europe.

The United Kingdom (UK) is another country where we have made some significant headway so far this year, with patients now using Actiste® as part of an ongoing clinical study in collaboration with Britain's National Health Service (NHS). Brighter's management believes that a positive outcome in this study could be a stepping stone, not only to a broader

commercialization in Europe, but could additionally provide international credibility for Brighter's ADMS solution with governments and healthcare providers around the world.

New possibilities in Saudi Arabia.

In the Kingdom of Saudi Arabia (KSA), the Communications and Information Technology Commission (CITC) has invited Brighter to apply for participation in the "Emerging Technologies Regulatory Sandbox" initiative. Its aim includes permitting innovative technologies to operate in KSA on a trial basis, exempted from the full weight of regulations. For Brighter's part, this could potentially remove or reduce the legal requirements on data processing and data roaming that have thus far hindered Brighter's efforts to commercialize our ADMS solution in KSA.

In connection with this, Brighter hosted KSA's Ambassador-designate to Sweden and Iceland, Her Excellency Einas Al-Shahwan, on a visit to the company's offices in Stockholm. Her Excellency was optimistic about Brighter and what we offer in terms of products and solutions.

Focus on financing and cost efficiency.

Unfortunately, Brighter's share-price performance, partly influenced by broader capital-market trends, continues to be a challenge. This was reflected in the 45% participation in the exercise of warrants of series TO7, corresponding to additional funds of approximately SEK 11.7 million before issuing costs. That said, we are very grateful towards everyone who participated, as the new funds are vital for maintaining

momentum in our ongoing commercialization, while the Board continues to explore different financing options going forward. We have also, with considerable success, continued our commitment to reduce our burn rate and refining our processes and ways-of-working across multiple functions. This is an ongoing effort.

Significant addition to the Board and increasing interest from healthcare providers.


I'm very pleased that Johnny Ludvigsson joined Brighter's Board during the second quarter. Johnny is one of the world's leading diabetes experts and has won numerous awards within his field over the years. He has deep knowledge and an extensive network across

the medical field that will be very valuable to Brighter as we continue the commercialization of Actiste®.

I am also very pleased that doctors in our key markets are expressing positive comments about Actiste®, both for addressing patient challenges and improving patient-caregiver interaction. This is crucial for our credibility when deepening our relationships with potential customers and decision-makers.

Finally, I'm happy to say that I've taken on the role as permanent CEO of Brighter. I thank the Board, our shareholders, customers and employees for their confidence in my leadership as we continue to realize the potential that Brighter has to offer.

Erik Lissner, CEO Brighter AB.



Why invest in Brighter?

Brighter is aiming to improve the lives of millions of people living with diabetes around the world. We offer an innovative technology platform for the healthcare sector which can increase the efficiency and lower the cost. We believe there are five simple and compelling reasons to invest in Brighter.

Our purpose - to improve the lives of millions of people living with diabetes while driving innovation and generating knowledge in the healthcare sector.

Diabetes is one of the fastest growing health challenges in modern times. Today, more than 537 million people around the world are affected by diabetes, and the numbers are predicted to nearly double by the year 2045. The cost for diabetes care is extensive – \$ 966 billion in 2021¹. Poor adherence to the medical regimen is a major clinical problem in the management of patients with diabetes, which can lead to unnecessary complications and increased cost for society. With our technology and innovative services in targeted markets, we aim to improve health outcomes and wellbeing amongst people living with diabetes and facilitate increased efficiency throughout the healthcare system.

Our IP portfolio - a strong asset in digital and connected healthcare.

Brighter has since the beginning built a strong IP portfolio in digital and connected healthcare.

With a large number of approved patents globally and many ongoing patent applications we consider the IP portfolio, and the commercial licensing opportunities it creates, as its own active business area with significant potential.

The Company has approved patents worldwide, including in Europe, the United States, India, Indonesia, Brazil, Japan, South Korea, China and Mexico.

Our products and solutions - in line with the global trends of digital healthcare.

The pandemic that quickly spread in 2020 increased the burden on health care systems throughout the world to near the breaking point. Now, with the massive growth of people diagnosed with diabetes and the rising cost for society, the need for intuitive, intelligent and connected medical products and services providing insights increase. Brighter's Actiste® and The Benefit Loop® (read more on pg 26) already support data-driven and mobile healthcare services that aim to simplify, streamline and improve the information flow of relevant and reliable data. The

ambition forward is to further develop our services in order to increase our offer of insights driven data analytics solutions. We aim to capitalize on an even larger share of Brighter's offering and accelerate our establishment in the market.



Our People - broad competence, experienced management and passionate team.

We have an experienced management team, with a strong track record of driving the business forward by building brand, creating global presence and connecting with key stakeholders in key markets. Our employees are truly passionate about medtech and digital development, all our functions are driving digital transformation in order to drive the business forward.

Our partners - important stakeholders in key markets.

Besides continuous contacts and projects with key opinion leaders, governments and healthcare providers, Brighter has established partnerships and agreements in all its prioritized markets. Among those are Al Danah Medical Company, one of the leading distributors of medical and biomedical equipment in Qatar. In the United Arab Emirates Brighter is working with a number of hospitals for the upcoming Actiste® pilot. In Indonesia - Padjadjaran University and hospitals have decided to drive a research project together with Brighter and we have a reseller agreement with Medico, Indonesia's leading provider of cloud-based healthcare-management systems. We have also established agreements to expand Brighter's sales channels in Sweden.

¹ IDF Diabetes Atlas 10th edition, <https://diabetesatlas.org/>

Significant events during Q2.

- The first patient has been prescribed the Actiste® solution in Qatar
- The first patient has been recruited for the Actiste® study in the United Kingdom
- The Saudi Arabia Communications and Information Technology Commission (CITC) has invited Brighter to apply for possible participation in the Emerging Technologies Regulatory Sandbox in the country
- Brighter's interim CEO Erik Lissner takes on a permanent role as the company's CEO
- The executive management and the Board of Directors announced their intention to exercise 3,821,474 warrants of series TO7, corresponding to a total of approximately SEK 0.3 million
- Brighter received approximately SEK 11.7 million before issuing costs through the exercise of the warrants of series TO7, corresponding to approximately 45 percent of the total number of outstanding warrants of series TO7
- The Annual General Meeting resolved to re-elect Clas Lindbergson, Åsa Sjöblom Nordgren, Karin O'Connor and Christer Trägårdh as ordinary board members, and to elect Johnny Ludvigsson as a new board member. Christer Trägårdh was re-appointed as Chairman of the Board.
- Mangold Insight published its second analysis of Brighter

Significant events after the end of Q2.

- Brighter receives ethical approval and import-clearance approval for pilot research with insulin-treated diabetes patients in the United Arab Emirates (UAE). This marks the final outstanding approval for the pilot.
- Brighter's Actiste® receives telecommunication type approval in the UAE.



Financial Summary.

April – June 2022.

- Net sales amounted to TSEK 312 (553)
- Operating result amounted to TSEK -43 616 (-46 936)
- Earnings before tax amounted to TSEK -43 892 (-68 324)
- Operating cash flow amounted to TSEK -29 122 (-31 327)
- Earnings per share, before and after dilution amounted to SEK -0.05 (-0.20)

January – June 2022.

- Net sales amounted to TSEK 536 (705)
- Operating result amounted to TSEK -88 992 (-91 691)
- Earnings before tax amounted to TSEK -90 447 (-116 628)
- Operating cash flow amounted to TSEK -60 380 (-76 506)
- Earnings per share, before and after dilution amounted to SEK -0.12 (-0.40)

Financial overview.

Amounts in TSEK	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021	Jan-Dec 2021	Jan-Dec 2020
Net turnover	312	553	536	705	1 266	1 665
Operating profit/loss	-43 616	-46 936	-88 992	-91 691	-185 480	-207 034
Net financial items	-277	-21 389	-1 455	-24 936	-24 400	-13 473
Profit/loss before tax	-43 892	-68 324	-90 447	-116 628	-209 880	-220 507
Balance sheet total	243 373	317 934	268 745	338 917	268 745	338 917
Shareholders' equity per share	0,28	0,72	0,30	0,82	0,59	1,23
Equity ratio	88%	78%	77%	74%	77%	74%

For definitions, see note 10

Comments on the financial results.

Financial results for April – June 2022.

In December 2021, the Board of Directors decided to sell all shares in the wholly owned subsidiary Camanio AB. This decision was taken in line with the Company's objective to streamline its operations to focus on Brighter's core business of data driven and connected diabetes care. Revenue and expenses, and gains and losses relating to the discontinuation of this segment have been removed from the results of continuing operations and are shown as a single line item on the face of the statement of comprehensive income ("Net result from discontinued operations") in accordance with IFRS 5.

Income.

Net sales were TSEK 312 (553). Capitalized expenditures for development work were TSEK 6 664 (11 132). Other operating income amounted to TSEK 1 377 (269) for the period.

Operating result.

Operating result for the period amounted to TSEK -43 616 (-46 936). Depreciation was TSEK -14 260 (-14 276). Brighter contributed TSEK -37 522 to the operating result. The rest refers to Nectarine Health.

Average headcount during the quarter (Full Time Equivalents – FTE) was down to 71 (83). The number of FTEs were 57 employees and 14 consultants. The staff cost amounted to TSEK -16 044 (-14 454) of which TSEK -10 031 relates to Brighter and the rest refers to Nectarine Health.

Cash flow.

At the start of the quarter, the Group had cash of TSEK 42 437 (43 282), decreasing to TSEK 18 353 (15 620) by the end of the period.

Cash flow from continuing operations operating activities amounted to TSEK -29 122 (-31 327). Investments amounted to TSEK

-4 638 (-10 342) of which investment of TSEK -4 638 (-10 342) in intangible assets, and TSEK -0 (0) in financial assets.

Net financing of TSEK 9 676 (14 780) after costs was realized during the period.

Total cash flow for continuing operations for the period amounted to TSEK -24 084 (-26 889).

Total cash flow for discontinued operations for the period amounted to TSEK 0 (-773).



Financial results for January–June 2022.

Income.

Net sales were TSEK 536 (705).

Capitalized expenditures for development work were TSEK 13 274 (22 033). Other operating income amounted to TSEK 1 434 (2 195) for the period.

Operating result.

Operating result for the period amounted to TSEK -88 992 (-91 691). Depreciation was TSEK -28 521 (-28 567). Brighter contributed TSEK -77 040 to the operating result. The rest refers to Nectarine Health.

Average headcount during the first half year (Full Time Equivalents – FTE) was down to 72 (88). The number of FTEs were 56 employees and 16 consultants. The staff cost amounted to TSEK -30 613 (-29 865) of which TSEK -18 686 relates to Brighter and the rest refers to Nectarine Health.

Financial position.

Capitalized expenditure for development work during the period amounted to TSEK 13 274 (22 033), of which TSEK 5 880 relates to the development in Brighter and TSEK 7 394 relates to Nectarine Health.

Book value of capitalized expenditure totalled TSEK 123 558 (166 272). Patents and trademarks were TSEK 8 798 (7 993). The total intangible

assets are TSEK 132 355 (184 270) of which TSEK 69 446 relates to Brighter and the rest to Nectarine Health.

Book value of property, plant and equipment totalled TSEK 20 947 (30 652) of which equipment tools and installations in use TSEK 13 138 (18 161). Right-of-use assets relating to the rental and leasing agreements for other assets held by the Group were TSEK 7 809 (12 491).

Financial assets had a book value of TSEK 2 612 (13 708). Inventory amounted to TSEK 25 207 (16 717) of which TSEK 20 670 relates to Brighter and the rest to Nectarine Health. Other current receivables, TSEK 41 891 (45 553) are mainly prepayments to Sanmina, for production of Actiste® devices.

At the end of the period the Group had equity of TSEK 213 894 (248 532), an equity ratio of 88% (78%).

The Group had long-term interest bearing debt of TSEK 4 375 (7 237).

Cash flow.

At the start of the year, the Group had cash of TSEK 26 896 (7 276), decreasing to TSEK 18 353 (15 620) by the end of the period.

Cash flow from continuing operations operating activities amounted to TSEK -60 380 (-76 506). Investments amounted to TSEK -13 928 (-22 744) of which

investment of TSEK -13 866 (-22 752) in intangible assets, and TSEK -0 (8) in financial assets.

Net financing of TSEK 65 765 (110 943) after costs was realized during the period.

Total cash flow for continuing operations for the period amounted to TSEK -8 543 (11 693).

Total cash flow for discontinued operations for the period amounted to TSEK 0 (-3 350).

Sales in Q2 2022.

For Actiste®, Brighter continues to focus on several key markets in the Middle East and Southeast Asia. Brighter's subsidiary Nectarine Health remains focused on commercialization in the United States with its solution Nectarine Health™ at Home.

During Q2 the first patient was prescribed an Actiste® device in Qatar, marking a significant step in Brighter's commercial strategy in the region. The sales focus during the quarter has been to continue working with the Company's Qatar distributor Al Danah, and to establish relationships with more hospitals and healthcare facilities in the country – with the aim of building a network of diabetes Centers of Excellence and, ultimately, improve the lives of people living with diabetes. Brighter has several conversations ongoing with some of Qatar's leading healthcare providers in both the public and private sectors.

Brighter is now nearing the next stage of its commercialization plans in the United Arab Emirates (UAE). A number of healthcare facilities have signed up for participation in the upcoming user pilot, initiated

together with the Emirates Health Services (EHS). During the quarter, the Company received ethical committee approval from EHS and is now set to run the three-month pilot that will involve 100 patients across several healthcare centers. The process to find patients suitable to participate in the pilot is ongoing and we are already approaching the targeted 100 patients for the pilot.

In Indonesia, the West Java user study in collaboration with Padjadjaran University is also making positive progress. 100 orally and insulin-treated type-2 diabetes patients have now been identified (comprising 65 patients from a public hospital and 35 patients from a private hospital) and all of the 100 have already signed the consent form to join the study.

During the quarter, Brighter has continued to build important relationships with Indonesian decision makers.

In the Kingdom of Saudi Arabia (KSA), the Communications and Information Technology Commission (CITC) has invited Brighter to apply for participation in the

“Emerging Technologies Regulatory Sandbox” initiative. Its aim includes permitting innovative technologies to operate in KSA on a trial basis, exempted from the full weight of regulations. For Brighter's part, this could potentially remove or reduce the legal requirements on data processing and data roaming that have thus far hindered our efforts to commercialize the Actiste® Diabetes Management as a Service solution in KSA.

Brighter expects that the developments in KSA could be a first step towards being able to help large numbers of people living with diabetes in a country where 18.7% of the adult population are diagnosed with diabetes, and as many as 43.6% of the population are undiagnosed diabetics². With the aim of opening new possibilities for Brighter in KSA, the country's Ambassador-designate to Sweden and Iceland, Her Excellency Einas Al-Shahwan, visited Brighter's office in Stockholm during the quarter.

Finally, in the United Kingdom (UK) the first patients are now onboarded in the ongoing Actiste® clinical study.



² IDF Diabetes Atlas 10th edition, <https://www.diabetesatlas.org/data/en/country/174/sa.html>

Future liquidity position.

Due to the low outcome from TO7 warrants and difficulties in divesting or finding financing for the subsidiary Nectarine Health the Company is at the time of publication of the Q2 report, facing liquidity problems. However, the board and management of Brighter AB are in intensive negotiations to finalize a solution to provide sufficient funds.

The board and management of the Company's subsidiary Nectarine Health are conducting separate negotiations to secure external financing.

Risks.

The principal risks and sources of uncertainty for Brighter include financial risks, such as the future earnings trend, financing, liquidity and currency and credit risks. In addition to market and commercialization risks there are risks associated with Brighter's operations, such as dependencies of suppliers and key personnel, obtaining necessary approval from authorities, product development, patents and intellectual property rights and product responsibility.

Further information on the Group risk exposure and risk assessment work can be found in Brighter's 2021 Annual Report pages 29–32, in Note 20 and in EU Growth Prospectus to be found on [Brighter's website](#) (in Swedish).

Shareholders.

On June 30, 2022, Brighter AB had about 15 188 shareholders, of which the ten largest represented approximately 19.48% of the capital and votes. The total number of shares amounted to 873 524 945 at the end of the period. The table illustrates the ten largest shareholders. Warrants have been issued on several occasions to employees as incentive and to the shareholders as part of financing solutions. There are currently two listed warrant series; TO5 and TO8. For further description and status of all the warrant programs please see Notes 21 and 24 of Brighter's 2021 Annual Report as well as our homepage under Investors.

Name	Number of shares	Ownership
1. Försäkringsbolaget Avanza Pension	57 434 328	6,58%
2. N.A Gruppen AB	20 100 000	2,30%
3. Thore Andre Nordbö	16 505 243	1,89%
4. Nordnet Pensionsförsäkring AB	16 130 456	1,85%
5. Wael Smith AB	15 915 133	1,82%
6. Mangold Fondkommission AB	10 955 413	1,25%
7. Solokvist AB	10 752 552	1,23%
8. Swedbank Försäkring AB	9 978 203	1,14%
9. Johan Misuri	6 300 000	0,72%
10. CBLUX-Erste Group BK AG Clients AC	6 137 360	0,70%



Financial Statements.

Consolidated statement of comprehensive income.

Amounts in TSEK	Note	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021
Continuing operations					
Net sales		312	553	536	705
Capitalized expenditure for development work		6 664	11 132	13 274	22 033
Other operating income		1 377	269	1 434	2 195
Total operating income		8 353	11 954	15 243	24 933
Raw materials and consumables		-1 564	-483	-5 606	-1 007
Other external costs	3, 7	-18 244	-29 528	-36 164	-55 765
Staff costs		-16 044	-14 454	-30 613	-29 865
Depreciation/amortization and write-offs of tangible and intangible assets		-14 260	-14 276	-28 521	-28 567
Other operating costs		-1 856	-149	-3 330	-1 421
Operating result		-43 616	-46 936	-88 992	-91 691
Other financial income		0	825	0	1 701
Result from participation in subsidiaries & associated companies		-64	0	-126	0
Financial expenses		-213	-22 214	-1 329	-26 638
Net financial items		-277	-21 389	-1 455	-24 936
Result from continuing operations before tax	6	-43 892	-68 324	-90 447	-116 628
Income tax		0	0	0	0
Net result from continuing operations		-43 892	-68 324	-90 447	-116 628
Net result from discontinued operations	9	0	-4 739	0	-9 491
Net result for the period		-43 892	-73 063	-90 447	-126 118
Other comprehensive income					
Translation differences on foreign operations		3 106	-10	3 106	-157
Total comprehensive income for the period		-40 786	-73 073	-87 341	-116 785
Attributable to the parent company's shareholders		-40 786	-73 073	-87 341	-116 785
Amounts in TSEK		Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021
Earnings per share before dilution	4	-0,05	-0,20	-0,12	-0,40
Earnings per share after dilution	4	-0,05	-0,20	-0,12	-0,40

Consolidated statement of financial position.

Amounts in TSEK	Note	Jun 30 2022	Jun 30 2021	Dec 31 2021
Capitalized expenditure for development work		123 558	166 272	135 281
Concessions, patents, licenses, trademarks and similar rights		8 798	7 993	8 251
Goodwill		0	10 005	0
Total intangible assets		132 355	184 270	143 532
Equipment, tools and installations		13 138	18 161	15 060
Right-of-use assets		7 809	12 491	10 784
Total property, plant and equipment		20 947	30 652	25 844
Other long-term securities		965	12 061	965
Other long-term receivables		1 647	1 647	1 647
Total financial assets		2 612	13 708	2 612
Total fixed assets		155 914	228 630	171 988
Inventories		25 207	16 717	26 278
Total inventories		25 207	16 717	26 278
Accounts receivable		217	529	409
Current tax assets		0	3 613	0
Other current receivables		41 891	45 553	42 639
Prepayments and accrued income		1 792	7 272	536
Total current receivables		43 899	56 967	43 583
Cash and cash equivalents	5	18 353	15 620	26 896
Total current assets		87 459	89 303	96 757
TOTAL ASSETS	6	243 373	317 934	268 745

Amounts in TSEK	Note	Jun 30 2022	Jun 30 2021	Dec 31 2021
Share capital		43 676	17 366	19 516
Other contributed equity		920 030	830 074	866 017
Retained earnings		-749 811	-598 907	-678 980
Total equity		213 895	248 533	206 553
Total equity attributable to parent company shareholders		213 895	248 533	206 553
Long term interest bearing debt		4 375	7 237	6 571
Other long term liabilities		0	0	0
Total long-term liabilities	5	4 375	7 237	6 571
Accounts payable		7 557	8 477	8 273
Other interest-bearing debt		3 580	33 141	31 609
Tax liabilities		855	2 619	762
Other current liabilities		2 767	2 701	2 894
Accruals and deferred income		10 345	15 227	12 082
Total current liabilities		25 104	62 164	55 621
TOTAL EQUITY AND LIABILITIES		243 373	317 934	268 745

Consolidated statement of changes in equity.

Amounts in TSEK	Share capital	Other contributed equity	Result carried forward (including result for the period)	Total equity
Balance at January 1, 2021	11 450	713 205	-472 632	252 023
Result for the period			-210 442	-210 442
Translation differences on foreign operations			4 095	4 095
Total comprehensive income			-206 347	-206 347
Transactions with shareholders				
New issues for cash	4 752	109 303	0	114 055
New issues for non-cash consideration	1 163	26 757	0	27 920
Issue costs		-19 191	0	-19 191
Total transactions with shareholders	5 916	116 869	0	122 785
Balance at June 30, 2021	17 366	830 074	-598 907	248 532
Transactions with shareholders				
New issues for cash	5 916	136 059	0	141 975
New issues for non-cash consideration	2 150	42 546	0	44 696
Issue costs		-25 794	0	-25 794
Total transactions with shareholders	8 066	152 811	0	160 877
Balance at December 31, 2021	19 515	866 016	-678 979	206 553
Balance at January 1, 2022	19 515	866 016	-678 979	206 553
Result for the period			-90 447	-90 447
Translation differences on foreign operations			3 106	3 106
Total comprehensive income	0	0	-87 341	-87 341
Transactions with shareholders				
New issues for cash	24 161	87 530	0	111 691
New issues for non-cash consideration	0	0	0	0
Issue costs	0	-17 009	0	-17 009
Total transactions with shareholders	24 161	70 521	0	94 682
Balance at June 30, 2022	43 676	936 537	-766 320	213 894

Consolidated statement of cash flows.

Amounts in TSEK	Note	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021
Operating result		-43 616	-46 935	-88 992	-91 691
Adjustment for items not included in the cash flow	8	14 260	14 223	28 521	28 567
Interest received		0	0	0	0
Interest paid		-108	-2 928	-568	-3 796
Cash flow from operating activities before change in working capital		-29 464	-35 641	-61 038	-66 920
Increase/decrease in inventories		92	-4 557	344	-8 045
Increase/decrease in operating receivables		-1 006	18 025	-1 142	14 706
Increase/decrease in operating liabilities		1 255	-9 154	1 456	-16 247
Total change in working capital		341	4 314	658	-9 586
Cash flow from operating activities		-29 122	-31 327	-60 380	-76 506
Investments in intangible assets		-4 638	-10 342	-13 866	-22 752
Investments in property, plant and equipment		0	0	0	0
Increase/decrease short-term financial assets		0	0	-62	0
Investment in financial assets		0	0	0	8
Cash flow from investment activities		-4 638	-10 342	-13 928	-22 744
Loans raised/paid		0	25 000	-27 173	232
New share issues and warrants		11 691	0	111 691	141 975
New share issue costs		-271	-3 380	-17 009	-19 191
Loans from parent company/to subsidiary		0	-7 300	0	-12 950
Amortization of debts and loans received/paid		-1 744	293	-1 744	710
Increase/decrease short-term financial liabilities		0	167	0	167
Cash flow from financing activities		9 676	14 780	65 765	110 943
Cash flow from continuing operations		-24 084	-26 889	-8 543	11 693
Cash flow from discontinued operations	9	0	-773	0	-3 350
Cash flow for the period		-24 084	-27 662	-8 543	8 343
Opening cash and cash equivalents		42 437	43 282	26 896	7 276
Closing cash and cash equivalents		18 353	15 620	18 353	15 620
Discontinued operations					
Cash flow from operating activities		0	-2 902	0	-8 037
Cash flow from investing activities		0	-4 711	0	-7 386
Cash flow from financing activities		0	6 840	0	12 073
Group total					
Cash flow from operating activities		-29 122	-34 229	-60 380	-84 543
Cash flow from investing activities		-4 638	-15 053	-13 928	-30 130
Cash flow from financing activities		9 676	21 620	65 765	123 016
Cash flow Group		-24 084	-27 662	-8 543	8 343

Parent company income statement.

Amounts in TSEK	Note	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021
Net Sales		30	0	32	16
Capitalized production costs		3 157	6 234	5 880	10 303
Other operating income		1 032	222	1 051	990
Total operating income		4 219	6 457	6 963	11 309
Other external costs	3, 7	-16 022	-26 059	-35 727	-46 675
Staff costs		-9 025	-7 172	-16 666	-14 656
Depreciation/amortization of tangible and intangible assets		-12 725	-12 718	-25 450	-25 436
Other operating costs		-364	-118	-580	-407
Total operating costs		-38 137	-46 068	-78 422	-87 174
Operating result		-33 918	-39 611	-71 459	-75 865
Result from participation in subsidiaries and associated companies		-64	0	-126	0
Other interest income and similar income		-1 983	767	-9 015	1 606
Tax arrears on tax assessment and other taxes		-1 126	0	-1 126	0
Interest expenses and similar expenses		0	-29 741	-343	-48 266
Total result from financial items		-3 174	-28 974	-10 611	-46 660
Result after financial items		-37 092	-68 584	-82 070	-122 525
Tax on result for the period		0	0	0	0
Result for the period		-37 092	-68 584	-82 070	-122 525

Parent company balance sheet.

Amounts in TSEK	Note	Jun 30 2022	Jun 30 2021	Dec 31 2021
Capitalized expenditure for development work		60 648	92 806	78 266
Concessions, patents, licenses, trademarks and similar rights		8 798	7 944	8 251
Total intangible assets		69 446	100 750	86 517
Equipment, tools and installations		13 022	16 832	14 927
Total property, plant and equipment		13 022	16 832	14 927
Shares in Group companies		10 386	64 422	10 693
Other long-term securities		965	12 060	965
Other long-term receivables		1 647	1 647	1 647
Total financial assets		12 997	78 128	13 305
Total fixed assets		95 465	195 710	114 749
Inventories		20 670	18 701	23 060
Total Inventories		20 670	18 701	23 060
Accounts receivable		0	0	0
Receivable on subsidiary		69 822	56 091	53 318
Prepaid/income taxes recoverable		1 830	0	1 270
Other receivables		40 709	48 408	40 811
Prepayments and accrued income		1 792	1 403	1 513
Total current receivables		114 153	105 902	96 912
Cash at bank and in hand		17 407	13 290	26 227
Total current assets		152 230	137 893	146 200
TOTAL ASSETS		247 694	333 604	260 949

Amounts in TSEK	Note	Jun 30 2022	Jun 30 2021	Dec 31 2021
Share capital		43 676	17 366	19 516
Development expenses fund		60 648	92 806	78 266
Restricted equity		104 324	110 172	97 782
Share premium		936 539	830 074	866 017
Result carried forward		-726 934	-524 499	-509 959
Result for the period		-82 070	-122 525	-234 593
Unrestricted equity		127 535	183 050	121 466
Total equity		231 859	293 222	219 247
Accounts payable		6 054	3 796	5 942
Other interest bearing debt		0	27 500	27 173
Other liabilities		1 185	1 753	1 127
Accruals and deferred income		8 597	7 332	7 459
Total current liabilities		15 835	40 381	41 701
TOTAL EQUITY AND LIABILITIES		247 694	333 604	260 949

Notes.

Note 1. Accounting policies.

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act. For the Parent Company, the interim report has been prepared in accordance with the Annual Accounts Act and the Swedish Securities Market Act in accordance with the provisions of RFR 2. For both the Group and the Parent Company the same accounting principles and bases for calculation have been applied as in its most recent Annual Report.

Significant accounting and valuation principles are detailed in Note 1 in Brighter's 2021 Annual Report. Important estimates and assumptions for accounting purposes can be found in Brighter's 2021 Annual Report in Note 3.

Note 2. General information.

The company's business is and trades as Brighter AB (publ) with corporate identity number 556736-8591. The company was founded in Sweden on July 5, 2007 and registered with the Swedish Companies Registration Office (Bolagsverket) on August 31, 2007. The company's business is regulated by and its shares have been issued in accordance with the Swedish Companies Act (2005:551). The provisions in the Articles of Association are no more far-reaching than stated in the Swedish Companies Act as regards amendment to the rights of shareholders. The Company's identification code for legal entities (LEI) is 5299001CH8KORXSJV047.

Currently Brighter AB has three subsidiaries. Brighter One AB holds options as part of the external financing of the Company and the incentive scheme. Brighter AB has a subsidiary company in the UAE called Brighter Software Trading L.L.C. The company is co-owned with AFAQ, but is 100% controlled by Brighter AB. Brighter AB also has a wholly controlled subsidiary, Pink Nectarine Health AB which in turn has two subsidiaries; one in the United Kingdom; Nectarine Health Solutions Limited and the other in the USA, Camanio Care Inc. Brighter is a purpose-driven Group comprising a number of companies and brands in the health technology sector. By introducing ground-breaking technology and new innovative services the objective of the Group at a global level is to help improve people's health and lives as well as paving the way for more efficient and sustainable use of society's resources. Besides the wholly owned and controlled subsidiaries. The registered office of the Board of Directors is in the municipality of Stockholm, at Borgarfjordsgatan 18, SE-164 40 Kista. Brighter AB is listed on the NASDAQ First North Growth Market (BRIG). Brighter's Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB. +46 8 5277 5020, ca@mangold.se, www.mangold.se.

For further information: www.brighter.se or ir@brighter.se. The figures in the report are reported in TSEK unless otherwise stated.

Note 3. Specification of other external costs.

Other external costs for the quarter of TSEK 18 244 (29 528) mainly consist of consultancy costs. Brighter's other external costs are TSEK 15 568 and the rest refers to Nectarine Health with TSEK 2 676. A Full time employee (FTE) consultant contributes in every way equal to an full time employee, but receives payment through invoices.

Note 4. Earnings per share.

TSEK	Apr-Jun 2022	Apr-Jun2021	Jan-Jun 2022	Jan-Jun 2021
Result for the period attributable 100% to the Parent Company's shareholders	-37 092	-68 584	-82 070	-122 525
Number of shares at end of period before dilution	723 644 682	347 318 433	723 644 682	347 318 433
Number of shares at end of period after dilution	877 536 997	351 330 485	877 536 997	351 330 485
Weighted average number of shares before dilution	773 604 770	347 318 433	693 069 170	307 880 802
Earnings per share as a weighted average before dilution	-0,05	-0.20	-0,12	-0,40
Earnings per share (SEK) as a weighted average after dilution	-0,05	-0.20	-0,12	-0,40

Note 5. Borrowing and net liabilities.

Amounts in TSEK	Jun 2022	Jun 2021	Dec 2021
Long-term			
Long-term interest-bearing debt	4 375	7 237	6 571
Short-term			
Liabilities relating to interest-bearing debt	3 580	33 141	31 609
Total borrowing	7 955	40 378	38 180
Short-term interest-bearing receivable	0	0	0
Cash and cash equivalents	18 353	15 620	26 896
Net debt interest-bearing liabilities	-10 398	24 758	11 284
Equity	213 895	248 533	206 553
Debt to equity ratio	-4,9%	10,0%	5,5%

Note 6. Segment information.

Sales from customers per segment.

TSEK	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021
Segments				
Brighter	0	0	1	0
Nectarine Health	314	309	535	705
Elimination	-2	244	0	0
Total sales from customers	312	553	536	705

Profit/loss before tax per segment.

TSEK	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021
Segments				
Brighter	-39 658	-70 219	-86 707	-123 983
Nectarine Health	-6 113	-5 781	-11 994	-12 386
Elimination	1 879	7 676	8 254	19 776
Total results before tax	-43 892	-68 324	-90 447	-116 594

Assets per segment.

TSEK	Jun 30 2022	Jun 30 2021	Dec 31 2021
Segments			
Brighter	253 931	342 090	268 180
Camario Care	0	41 679	0
Nectarine Health	69 510	55 336	62 470
Elimination	-80 068	-121 170	-61 905
Total assets	243 374	317 934	268 745

Liabilities per segment.

TSEK	Jun 30 2022	Jun 30 2021	Dec 31 2021
Segments			
Brighter	22 944	49 686	51 558
Camario Care	0	21 280	0
Nectarine Health	77 005	54 791	62 633
Elimination	-70 471	-56 356	-52 000
Total liabilities	29 479	69 401	62 191

Note 7. Transactions with affiliated parties.

From January 1 – June 30, Erik Lissner invoiced the amount of TSEK 1 359 for his assignment as acting CEO.

Note 8. Specification of items not included in the cash flow.

Amounts in TSEK	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021
Depreciation/amortization of tangible and intangible assets	14 260	14 223	28 521	28 567
Total	14 260	14 223	28 521	28 567

Note 9. Discontinued operations.

In December 2021, the Board of Directors decided to sell all shares in the wholly owned subsidiary Camanio AB. This decision was taken in line with the Company's objective is to streamline its operations to focus on Brighter's core business of data-driven and connected diabetes care. Revenue and expenses, and gains and losses relating to the discontinuation of this segment have been removed from the results of continuing operations and are shown as a single line item on the face of the statement of comprehensive income ("Net result from discontinued operations") in accordance with IFRS 5. The operating results of the discontinued operation up to its disposal and the effect of remeasurement and disposal of assets that were classified as held for sale were as follows:

Operating activities of discontinued operations.

Amounts in TSEK	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021
Net sales	0	1 046	0	3 079
Capitalized expenditure for development work	0	3 954	0	6 629
Other operating income	0	161	0	361
Total operating income	0	5 162	0	10 069
Raw materials and consumables	0	-5 533	0	-7 418
Other external costs	0	190	0	-2 949
Staff costs	0	-3 919	0	-7 695
Depreciation and amortization	0	-613	0	-1 369
Other operating costs	0	-10	0	-105
Operating result	0	-4 722	0	-9 467
Other financial income	0	0	0	31
Financial expenses	0	-16	0	-55
Net financial items	0	-16	0	-24
Result from discontinuing operations before tax	0	-4 739	0	-9 491
Income tax	0	0	0	0
Net operating result from discontinued operations	0	-4 739	0	-9 491
Profit/loss on re-evaluation	0	0	0	0
Profit/loss on disposal	0	0	0	0
Tax liabilities	0	0	0	0
Net profit/loss from discontinued operations	0	-4 739	0	-9 491

Cash flow of discontinued operations.

Amounts in TSEK	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021
Cash flow of operating activities before changes in working capital	0	-4 128	0	-8 153
Cash flow from operating activities	0	-2 901	0	-8 037
Cash flow from investing activities	0	-4 711	0	-7 386
Cash flow from financing activities	0	6 840	0	12 073
Cash flow from discontinued operations	0	-772	0	-3 350
Opening cash and cash equivalents	0	1 639	0	4 217
Closing cash and cash equivalents	0	867	0	867

Note 10. Financial key figures.

Definition of key figures.

Net sales	Sales to external customers
Operating profit/loss	Profit/loss before financial items
Profit/loss for the period	Profit/loss after financial items
Earnings per share	Shareholders' equity via the number of outstanding shares before dilution
Operating margin %	Total income via operating profit/loss
Equity ratio %	Shareholders' equity via balance sheet total
Debt to equity ratio	Interest-bearing liabilities in relation to shareholders' equity
Net debt	Interest-bearing liabilities less interest-bearing assets and cash and cash equivalents
Working capital	All current assets minus current liabilities
Net financial items	Financial income minus financial costs
Balance sheet total	Total assets on balance sheet
Other external costs	All costs included in operating profit/loss, except for costs of goods sold, personnel costs and depreciation and share of earnings from associated companies

Financial calendar.

Interim Report Q3 2022

November 9 2022

Interim Report Q4 2022

February 24 2023*

Annual Report 2022

April 13 2023*

**Preliminary date*



Submission of interim report.

Stockholm, August 25, 2022.
Brighter AB (publ).

The Board of Directors and the CEO certify that the interim report for the period provides a fair view of the operations, financial position and results of the Parent Company and the Group, and describes material risks and uncertainties facing the Parent Company and the companies included in the Group.

Christer Trägårdh
Chairman of the Board

Johnny Ludvigsson
Board Member

Åsa Sjöblom Nordgren
Board Member

Clas Lindbergson
Board Member

Karin O'Connor
Board Member

Erik Lissner
CEO

Review by the auditor.

This interim report has not been reviewed by the company's auditor.

About Brighter.

Brighter is a medtech company that focuses on a number of challenges driven by global changes in society. The challenges are largely based on demographic and social shifts in the population, combined with limited resources and increasing costs in healthcare. By introducing groundbreaking technology and innovative services, Brighter's aim is to improve health outcomes and wellbeing amongst the global population and facilitate increased efficiency throughout the healthcare system.

Proactive and data driven medical care.

Brighter has developed unique solutions and services based on patented technology that aim to facilitate more proactive, efficient and data driven medical care, primarily with regard to diabetes under the Actiste® brand family. The solutions are based on a concept that Brighter refers to as The Benefit Loop® – a personal, holistic and data centered approach to medical care. The Benefit Loop is based on a Multi-Sided Market Platform strategy, in which Brighter, by increasing access to health data, aims to create value for all stakeholders in the care chain: patients, their relatives and close associates, healthcare providers, research institutes, the pharmaceutical industry, and society as a whole.

Digital care and support in the home.

The fully controlled subsidiary Nectarine Health, which focus on innovative technology and services for care and support in the home, has developed a remote monitoring solution using AI technology to give seniors the confidence to live independently at home for longer, without having to compromise their privacy or dignity, feeling safe and secure knowing that if they experience a health issue, help is always near.

The fully own subsidiary Camanio and the company's holding in Blodtrycksdoktorn were divested in December 2021.



For further information, please contact:

Erik Lissner, CEO


Phone: +46 72 999 38 60

E-mail: erik.lissner@brighter.se

Christopher Robinson, CFO

Phone: +46 70 777 40 14

E-mail: christopher.robinson@brighter.se



Brighter AB (publ) 556736-8591 +46 (0)8-550 088 20

Borgarfjordsgatan 18
164 40 Kista

www.brighter.se

info@brighter.se

Investor relations:
ir@brighter.se

Brighter